Halozyme Therapeutics, Inc. HALO
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 2.49% | 27.68% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.49% | 27.68% | |||
| Cost of Revenue | 3.20% | 1.94% | |||
| Gross Profit | 2.29% | 37.61% | |||
| SG&A Expenses | 2.18% | -1.53% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.41% | 0.60% | |||
| Operating Income | 2.54% | 55.90% | |||
| Income Before Tax | 2.01% | 57.99% | |||
| Income Tax Expenses | -20.74% | 81.61% | |||
| Earnings from Continuing Operations | 7.45% | 53.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.45% | 53.23% | |||
| EBIT | 2.54% | 55.90% | |||
| EBITDA | 2.33% | 47.98% | |||
| EPS Basic | 10.74% | 54.36% | |||
| Normalized Basic EPS | 5.30% | 59.19% | |||
| EPS Diluted | 5.79% | 55.74% | |||
| Normalized Diluted EPS | 1.01% | 60.18% | |||
| Average Basic Shares Outstanding | -2.96% | -0.74% | |||
| Average Diluted Shares Outstanding | 1.15% | -1.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||